On the stock market since 2021, it operates in the world of health and science. It has 1,895 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 311% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 311% a year on average.
The company sells $1.1B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $221.4M against $1.1B in annual sales.
The stock sits at $0.55. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, BBLN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BBLN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.